Resatorvid

CAS No. 243984-11-4

Resatorvid( TAK-242,CLI-095 )

Catalog No. M22910 CAS No. 243984-11-4

Resatorvid (TAK-242) is a selective inhibitor of Toll-like receptor 4 (TLR4). Resatorvid inhibits IL-6, TNF-R and NO production (IC50s: 1.3 nM, 1.9 nM, and 1.8 nM).Resatorvid suppresses the production of NO, TNF-α, and IL-6 from LPS-stimulated human peripheral blood mononuclear cells (PBMCs, IC50s: 11-33 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 In Stock
5MG 87 In Stock
10MG 150 In Stock
25MG 410 In Stock
50MG 538 In Stock
100MG 862 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Resatorvid
  • Note
    Research use only, not for human use.
  • Brief Description
    Resatorvid (TAK-242) is a selective inhibitor of Toll-like receptor 4 (TLR4). Resatorvid inhibits IL-6, TNF-R and NO production (IC50s: 1.3 nM, 1.9 nM, and 1.8 nM).Resatorvid suppresses the production of NO, TNF-α, and IL-6 from LPS-stimulated human peripheral blood mononuclear cells (PBMCs, IC50s: 11-33 nM).
  • Description
    Resatorvid (TAK-242) is a selective inhibitor of Toll-like receptor 4 (TLR4). Resatorvid inhibits IL-6, TNF-R and NO production (IC50s: 1.3 nM, 1.9 nM, and 1.8 nM).Resatorvid suppresses the production of NO, TNF-α, and IL-6 from LPS-stimulated human peripheral blood mononuclear cells (PBMCs, IC50s: 11-33 nM). Resatorvid (1-100 nM; 15 minutes; PBMCs cells) markedly inhibits the LPS-induced phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), p38, and JNK/SAPK as well as degradation of IκBβ at a concentration of 100 nM. Resatorvid (1-100 nM; 4 hours) inhibits mRNA expression of IL-6 and TNF-α induced by LPS and IFN-γ in RAW264.7 cells.In ApoE knockout and wild-type mice, Resatorvid (0.3 mg/kg; intraperitoneal injection; twice a week; for 4 weeks) treatment inhibits serum autoantibodies (ANA and anti-dsDNA), cytokines (IFN-γ, TNF-α, IL-1β), lung inflammation, and intima-media thickness in brachiocephalic artery.
  • In Vitro
    RT-PCRCell Line:RAW264.7 cells Concentration:1 nM, 10 nM, 100 nM Incubation Time:4 hours Result:TNF-α and IL-6 mRNA expression levels were clearly suppressed at concentrations of 10 to 100 nM.Western Blot Analysis Cell Line:PBMCs cells Concentration:1 nM, 10 nM, 100 nM Incubation Time:15 minutes Result:The phosphorylation of mitogen-activated protein kinases induced by LPS was also inhibited in a concentration-dependent manner.
  • In Vivo
    Animal Model:Male C57BL/6 mice (8-12 weeks of age) treated with lipopolysaccharide (LPS)Dosage:3?mg/kg Administration:Intraperitoneal injection; for 2 days Result:Pretreatment of mice reduced or reversed all the detrimental effects of LPS.
  • Synonyms
    TAK-242,CLI-095
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    TLR4|TNF-R
  • Research Area
    Inflammation
  • Indication
    Septic shock

Chemical Information

  • CAS Number
    243984-11-4
  • Formula Weight
    361.82
  • Molecular Formula
    C15H17ClFNO4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (276.38 mM; Need ultrasonic)
  • SMILES
    O=S([C@H]1C(C(OCC)=O)=CCCC1)(NC2=CC=C(C=C2Cl)F)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ii M, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol, 69 (4), 1288-95, Apr 2006.
molnova catalog
related products
  • CU-115

    CU-115 is a selective antagonist of TLR8 with IC50s of 1.04 μM and >50 μM for TLR8 and TLR7, respectively.

  • TLR7/8-IN-1

    TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor from patent WO2019220390 (compound 2b), is a valuable compound for autoimmune disease research.

  • TLR7/8 agonist 1

    TLR7/8 agonist 1 is a toll-like receptor TLR7/TLR8 agonist with anticancer and antiviral activities and can be used to study immune-related diseases.